Diagnostics

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Understanding the effect of other diseases on blood biomarker levels in AD

Screening for delirium in individuals with dementia

Biomarkers of delirium incidence and severity

Biomarkers for risk assessment and early diagnosis of AD

Next steps in dementia biomarkers

Considering non-cognitive markers in dementia

What do we understand about the secretion of brain p-tau in AD?

Next steps in VCID research: molecular targets and fluid biomarkers

Importance of standardizing biomarker protocols in the diagnosis of AD

New diagnostic criteria for apathy in neurocognitive disorders

The prodromal phases of Alzheimer’s disease